Pfizer and Taisho Pharmaceutical have signed an agreement to collaborate on a new schizophrenia medication.
The two firms are to research, develop and bring to market TS-032, which was discovered by Taisho and is currently in preclinical development.
Under the deal, Taisho will receive an initial sum of $22m from Pfizer, as well as milestone payments tied to the progress of the drug’s development.
TS-032 is a novel mGluR (metabotropic glutamate receptor) agonist that may offer a new solution for central nervous system disorders.
Although the characteristics of mGluR are still only partly understood, it is believed to play a role in the transmission of glutamate and other substances in the brain.
Dr Martin Mackay, president of Pfizer Global Research and Development, said: “We are pleased to partner with Taisho in this important area of research.
“Schizophrenia is among the most chronic and disabling of mental health conditions and there still remains a significant need for novel treatment advances with improved efficacy and fewer side-effects.
“Pfizer has a long-standing strength in developing and commercialising medications for the treatment of psychiatric illnesses, including Zoloft, Xanax and Geodon.
“This agreement highlights our commitment to pursue opportunities that align strategically with our key development priorities and strengthen our pipeline.”
Copyright © PA Business 2008